Cargando…

A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice

Safinamide is an approved drug for the treatment of motor fluctuations in Parkinson’s disease (PD). Scarce data are available on its use in clinical practice. A group of Spanish movement disorders specialists was convened to review the use of safinamide across different clinical scenarios that may g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pagonabarraga, Javier, Arbelo, José Matías, Grandas, Francisco, Luquin, Maria-Rosario, Martínez Martín, Pablo, Rodríguez-Oroz, Mari Cruz, Valldeoriola, Francesc, Kulisevsky, Jaime
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139287/ https://www.ncbi.nlm.nih.gov/pubmed/32197462 http://dx.doi.org/10.3390/brainsci10030176

Ejemplares similares

Erratum: Pagonabarraga, J.; et al. A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice. Brain Sci. 2020, 10, 176
por: Pagonabarraga, Javier, et al.
Publicado: (2020)

Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study
por: Martí-Andrés, Gloria, et al.
Publicado: (2019)

Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus
por: Stocchi, Fabrizio, et al.
Publicado: (2022)

Long-term Efficacy of Safinamide on Parkinson’s Disease Chronic Pain
por: Cattaneo, Carlo, et al.
Publicado: (2018)

Present and Future of Parkinson’s Disease in Spain: PARKINSON-2030 Delphi Project
por: Santos García, Diego, et al.
Publicado: (2021)

Impact of Safinamide on Patient-Reported Outcomes in Parkinson’s Disease
por: Espinoza-Vinces, Christian, et al.
Publicado: (2023)

A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease
por: Kulisevsky, Jaime, et al.
Publicado: (2022)

Consensus on the Definition of Advanced Parkinson's Disease: A Neurologists-Based Delphi Study (CEPA Study)
por: Luquin, Maria-Rosario, et al.
Publicado: (2017)

COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015), a global –clinical evaluations, serum biomarkers, genetic studies and neuroimaging– prospective, multicenter, non-interventional, long-term study on Parkinson’s disease progression
por: Santos-García, Diego, et al.
Publicado: (2016)

Erratum to: COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015), a global –clinical evaluations, serum biomarkers, genetic studies and neuroimaging– prospective, multicenter, non-interventional, long-term study on Parkinson’s disease progression
por: Santos-García, Diego, et al.
Publicado: (2016)

Validation study of the Parkinson’s Fatigue Scale in advanced Parkinson’s disease
por: Martinez-Martin, Pablo, et al.
Publicado: (2019)

Prevalence of Advanced Parkinson’s Disease in Patients Treated in the Hospitals of the Spanish National Healthcare System: The PARADISE Study
por: Martínez-Castrillo, Juan Carlos, et al.
Publicado: (2021)

Psychometric Properties of the Apathy Scale in Advanced Parkinson's Disease
por: Wetmore, John B., et al.
Publicado: (2019)

The effects of safinamide on dysphagia in Parkinson’s disease
por: Hirano, Makito, et al.
Publicado: (2023)

Effects of safinamide on pain in patients with fluctuating Parkinson's disease
por: Grigoriou, Sotirios, et al.
Publicado: (2021)

Safinamide: an add-on treatment for managing Parkinson’s disease
por: Müller, Thomas
Publicado: (2018)

SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease
por: Gómez-López, Ana, et al.
Publicado: (2021)

Investigational agents in the treatment of Parkinson’s disease: focus on safinamide
por: Malek, Naveed M, et al.
Publicado: (2012)

Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide
por: Stocchi, Fabrizio, et al.
Publicado: (2016)

Emerging approaches in Parkinson’s disease – adjunctive role of safinamide
por: Müller, Thomas
Publicado: (2016)

The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease
por: Abbruzzese, Giovanni, et al.
Publicado: (2021)

Validation of a simple screening tool for early diagnosis of advanced Parkinson’s disease in daily practice: the CDEPA questionnaire
por: Martinez-Martin, Pablo, et al.
Publicado: (2018)

Tremor Types in Parkinson Disease: A Descriptive Study Using a New Classification
por: Gironell, Alexandre, et al.
Publicado: (2018)

Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
por: Loprete, Luca, et al.
Publicado: (2016)

Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson’s Disease
por: Cattaneo, Carlo, et al.
Publicado: (2017)

The Efficacy of Safinamide in the Management of Parkinson's Disease: A Systematic Review
por: Sharaf, Joudi, et al.
Publicado: (2022)

Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide
por: Pauletti, Caterina, et al.
Publicado: (2023)

A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial(1)
por: Abbruzzese, Giovanni, et al.
Publicado: (2021)

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
por: Borgohain, Rupam, et al.
Publicado: (2014)

Facial Emotion Recognition Impairment in Patients with Parkinson's Disease and Isolated Apathy
por: Martínez-Corral, Mercè, et al.
Publicado: (2010)

Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now?
por: Rosa-Grilo, Miguel, et al.
Publicado: (2017)

Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease
por: Valldeoriola, Francesc, et al.
Publicado: (2021)

The impact of dopaminergic treatment over cognitive networks in Parkinson's disease: Stemming the tide?
por: Aracil‐Bolaños, Ignacio, et al.
Publicado: (2021)

Impact of SAfinamide on Depressive Symptoms in Parkinson’s Disease Patients (SADness-PD Study): A Multicenter Retrospective Study
por: Peña, Esteban, et al.
Publicado: (2021)

Effects of Safinamide on Pain in Fluctuating Parkinson’s Disease Patients: A Post-Hoc Analysis
por: Cattaneo, Carlo, et al.
Publicado: (2017)

Safinamide improves sleep and daytime sleepiness in Parkinson’s disease: results from the SAFINONMOTOR study
por: Santos García, Diego, et al.
Publicado: (2021)

Pain Improvement in Parkinson’s Disease Patients Treated with Safinamide: Results from the SAFINONMOTOR Study
por: Santos García, Diego, et al.
Publicado: (2021)

Focus on Depression in Parkinson's Disease: A Delphi Consensus of Experts in Psychiatry, Neurology, and Geriatrics
por: Agüera-Ortiz, Luis, et al.
Publicado: (2021)

Parkinson's Disease: Impulsivity Does Not Cause Impulse Control Disorders but Boosts Their Severity
por: Marín-Lahoz, Juan, et al.
Publicado: (2018)

Pattern of Regional Cortical Thinning Associated with Cognitive Deterioration in Parkinson’s Disease
por: Pagonabarraga, Javier, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_v5at8626ab65d62ha6a26nmjnj